2Seventy Bio Inc reports results for the quarter ended September 30 - Earnings Summary

2Seventy Bio

12/11/2024 15:35

* 2Seventy Bio Inc  TSVT.OQ  reported a quarterly adjusted
loss
of 19 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.00.  The mean expectation of six analysts
for the quarter was for a loss of 24 cents per share. Wall
Street expected results to range from -35 cents to -7 cents per
share.
    * Revenue rose 12.5% to $13.53 million from a year ago;
analysts
expected $15.04 million. 
    * 2Seventy Bio Inc's reported EPS for the quarter was a loss
of 19
cents​.
    * The company reported a quarterly loss of $9.93 million.
    * 2Seventy Bio Inc shares had fallen by 2.5% this
quarter and
gained 7.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 39.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for 2Seventy Bio Inc
is 8.00 
This summary was machine generated from LSEG data November 12 at
03:35 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.24          -0.19          Beat
 Jun. 30 2024      -0.65          0.45           Beat
 Mar. 31 2024      -0.81          -1.01          Missed
 Dec. 31 2023      -0.99          -1.11          Missed